By Dr. Quoc Dang, DO — Medical Director, WeightLossPills.com
Since tirzepatide received FDA approval for obesity management under the brand name Zepbound in late 2023, the most common question I get from patients researching their options is some version of: which one is better, Wegovy or Zepbound?
My answer is that it depends, and the reasons why it depends are worth understanding because they affect which medication is likely to serve a given patient better. These are not interchangeable drugs. They have different mechanisms, different average efficacy profiles, and different side effect characteristics that matter in clinical decision making.
Table of Contents
The Mechanism Difference
Semaglutide, the active ingredient in Wegovy, is a GLP-1 receptor agonist. It works by mimicking GLP-1, a hormone produced in the gut that stimulates insulin secretion, slows gastric emptying, and signals satiety to the brain.
Tirzepatide, the active ingredient in Zepbound, is a dual agonist. It activates both the GLP-1 receptor and the GIP receptor. GIP is another gut hormone that influences energy metabolism, fat storage, and insulin sensitivity, and its receptor has a distribution in the brain and metabolic tissues that partially overlaps with and partially complements GLP-1’s effects.
The practical implication of the dual mechanism is that tirzepatide appears to have a stronger overall metabolic effect than semaglutide alone, particularly in the context of insulin resistance. This helps explain why it produces higher average weight loss in clinical trials.
What the Clinical Trial Data Shows
The SURMOUNT-1 trial of tirzepatide showed average weight loss of 15 percent of body weight at the 5 milligram dose, 19.5 percent at the 10 milligram dose, and 20.9 percent at the 15 milligram dose over 72 weeks. These are substantially higher than the average of approximately 14.9 percent seen with semaglutide 2.4 milligrams in the STEP-1 trial over 68 weeks.
In a direct comparison, the SURMOUNT-5 trial found that tirzepatide produced an average weight loss of 20.2 percent compared to 13.7 percent for semaglutide over 72 weeks, a statistically significant difference of about 6.5 percentage points.
This does not mean tirzepatide is the right choice for everyone. Averages describe populations, not individuals. Some patients respond exceptionally well to semaglutide and achieve results that exceed the tirzepatide average. The variation in individual response is large enough that trial averages are a guide, not a prediction.
Side Effect Profiles
Both medications share a common gastrointestinal side effect profile: nausea, vomiting, diarrhea, and constipation are the most frequently reported adverse events with both drugs. The incidence of these side effects is generally similar between the two, though some patients find one more tolerable than the other for reasons that are not fully understood.
There are some differences worth noting. Tirzepatide may produce slightly less nausea than semaglutide at equivalent doses in some patients, possibly because GIP receptor activation in the gut has an opposing effect to GLP-1 on gut motility. Some clinicians also observe that patients who have struggled with gastrointestinal side effects on semaglutide sometimes tolerate tirzepatide better.
Both medications carry the same class-level warnings regarding medullary thyroid carcinoma and pancreatitis. Neither is appropriate for patients with a personal or family history of medullary thyroid carcinoma or MEN-2 syndrome.
Cost and Access
As of 2025, both medications are expensive without insurance coverage, with list prices in the range of $1,300 to $1,500 per month. Coverage varies considerably by insurance plan. Manufacturer savings programs exist for commercially insured patients but do not apply to Medicare or Medicaid beneficiaries.
Compounded versions of both medications have been available during shortage periods, though this situation continues to evolve as branded supplies have normalized. Patients considering compounded formulations should do so only with guidance from a knowledgeable physician and from licensed compounding pharmacies that meet regulatory standards.
Which One Should You Take
My general approach is to start with tirzepatide for patients who have no specific contraindications, given its superior average efficacy. For patients who have previously been on semaglutide and tolerated it well, or who have insurance that covers semaglutide but not tirzepatide, semaglutide remains an excellent option.
The right choice also depends on a patient’s baseline insulin resistance, their side effect tolerance during titration, their insurance coverage, and what their physician is most experienced managing.
Patients comparing weight loss injections and weighing the differences between Wegovy and Zepbound will benefit from having a detailed conversation with a physician who is current on the trial data and who knows their specific medical history. The differences between these two medications are real and clinically meaningful, and the decision is worth making thoughtfully rather than defaulting to whatever is most recently advertised.
Both represent a genuine advance over what was available even five years ago. The goal is not to find the theoretically best drug on average but the right drug for the specific patient sitting in the chair.
Dr. Quoc Dang, DO, is a board-certified physician and Medical Director at WeightLossPills.com, where he specializes in medically supervised weight management and GLP-1 therapy.